Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast CancerHeikki Joensuu, Jorma Isola, Akseli Hemminki et al.|New England Journal of Medicine|2006Cited by 1.4k
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trialSherene Loi, Christos Sotiriou, Stefan Michiels et al.|Annals of Oncology|2014Cited by 1.3k
Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer TrialHeikki Joensuu, Pirkko‐Liisa Kellokumpu‐Lehtinen, Petri Bono et al.|Journal of Clinical Oncology|2009Cited by 459
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trialKarim Fizazi, Mika Mustonen, Christophe Massard et al.|The Lancet Oncology|2014Cited by 194